研究单位：[1]DualityBio Inc.[2]TOI Clinical Research,Cerritos,California,United States,90703[3]Washington Cancer Institute at MedStar Washington Hospital Center,Washington,District of Columbia,United States,20010[4]D&H Cancer Research Center LLC,Margate,Florida,United States,33063[5]BRCR Medical Center Inc.,Plantation,Florida,United States,33322[6]BRCR Medical Center Inc.,Tamarac,Florida,United States,33321[7]Southeastern Regional Medical Center, LLC,Newnan,Georgia,United States,30265[8]Kapi'olani Medical Center for Women and Children,Honolulu,Hawaii,United States,96826[9]Women's Cancer Care,Covington,Louisiana,United States,70433[10]Massachusetts General Hospital,Boston,Massachusetts,United States,02214[11]David C. Pratt Cancer Center,Saint Louis,Missouri,United States,63141[12]Northwell Health,Lake Success,New York,United States,11042[13]Laura & Isaac Perlmutter Cancer Center at NYC Langone Health,New York,New York,United States,10016[14]Memorial Sloan Kettering Cancer Center,New York,New York,United States,10065[15]Gabrail Cancer Center,Canton,Ohio,United States,44718[16]University of Oklahoma,Oklahoma City,Oklahoma,United States,73104[17]Thomas Jefferson University,Philadelphia,Pennsylvania,United States,19107[18]Tennessee Oncology,Nashville,Tennessee,United States,37203[19]Swedish Cancer Institute,Seattle,Washington,United States,98104[20]Macquarie Clinical Trials Unit,Sydney,New South Wales,Australia,2109[21]Integrated Clinical Oncology Network Pty Ltd (Icon),South Brisbane,Queensland,Australia,4101[22]The first affiliated hospital of Bengbu medical college,Bengbu,Anhui,China[23]Anhui provincial hospital,Hefei,Anhui,China[24]The Second Hospital of Anhui Medical University,Hefei,Anhui,China[25]Beijing Cancer Hospital,Beijing,Beijing,China[26]Cancer Hospital Chinese Academy of Medical Science,Beijing,Beijing,China[27]The First Hospital of Jilin University,Jilian,Changchun,China[28]Huizhou First Hospital,Guangzhou,Guangdong,China[29]Sun Yat-Sen Memorial Hospital of Zhongshan University,Guangzhou,Guangdong,China[30]The First affiliated hospital, Sun Yat-sen University,Guangzhou,Guangdong,China[31]Cancer Hospital of Guangxi Medical University,Nanning,Guangxi,China[32]The First people's hospital of Yulin,Yulin,Guangxi,China[33]Affiliated Hospital of Hebei University,Baoding,Hebei,China[34]Henan cancer Hospital,Zhengzhou,Hehan,China[35]The First Affiliated Hospital of Zhengzhou University,Zhengzhou,Henan,China[36]Union hospital Tongji Medical college Huazhong university of science and technology,Wuhan,Hubei,China[37]Hunan People's Provincial Hospital,Changsha,Hunan,China[38]Affiliated Hospital of Jiangnan University,Wuxi,Jiangsu,China[39]Xuzhou Cancer Hospital,Xuzhou,Jiangsu,China[40]Jiangxi maternal and child health hospital,Nanchang,Jiangxi,China[41]The Third Hospital of Nanchang,Nanchang,Jiangxi,China[42]The First Hospital of China Medical University,Shenyang,Liaoning,China[43]Central hospital affiliated to Shandong first medical university,Jinan,Shandong,China[44]Shandong Cancer hospital & institute,Jinan,Shandong,China[45]Linyi Tumor Hospital,Liaocheng,Shandong,China[46]Zibo Central hospital,Zibo,Shandong,China[47]Yantai Yuhuangding Hospital,Yantai,Shangdong,China[48]Fudan University,Shanghai,Shanghai,China[49]Tianjin Medical university cancer institute & hospital,Tianjin,Tianjin,China[50]1st affliated hospital of Zhejiang University,Hangzhou,Zhejiang,China[51]The second affiliated hospital of Zhejiang University School of Medicine,Hangzhou,Zhejiang,China[52]Zhejiang Cancer Hospital,Hangzhou,Zhejiang,China[53]BRCR Global Puerto Rico LLC.,Mayaguez,Puerto Rico,00682
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303 in subjects with advanced solid tumors that express HER2.
